Background
Methods
Human subjects
Characteristics | Non-smokersa (N = 17) | Smokersa (N = 30) | COPD GOLD stages I-II (N = 31) | COPD GOLD stages III-IV (N = 17) | P valuec |
---|---|---|---|---|---|
Number of males (%) | 12 (70) | 20 (67) | 22 (70) | 12 (70) | NS |
Age (years) | 45 (20–77) | 62 (25–78) | 67 (50–81) | 60 (49–73) | P ≤ 0.02d |
Pack-yrs. of smoking | 0 | 41 (15–80) | 53 (20–100) | 58 (10–114) | P ≤ 0.03e |
Number of current smokers (%) | 0 (0) | 13 (43) | 18 (58) | 3 (18) | P ≤ 0.02f |
FEV1(% of predicted)b | 93 (79–104) | 94 (65–115) | 75 (51–118) | 29 (10–48) | P ≤ 0.008g |
FEV1/FVC (% of predicted)b | 80 (73–84) | 78 (71–89) | 61 (47–68) | 43 (25–60) | P < 0.001h |
ADAM15mRNA Levels in Lungs | 1 ± 0.6 | 0.84 ± 0.6 | 0.82 ± 0.5 | 2 ± 0.8 | P = 0.001i |
Characteristics | Non-smokersa (N = 6) | Smokersa (N = 19) | COPD Patients (N = 14) | P valuec |
---|---|---|---|---|
Number of males (%) | 5 (83) | 7 (37) | 7 (50) | NS |
Age (years) | 59 (46–73) | 64 (51–75) | 66 (60–74) | NS |
Pack-yrs. of smoking | 0 | 29 (12–68) | 43 (7–160) | P < 0.001d |
Number of current smokers (%) | 0 (0) | 7 (37) | 6 (43) | NS |
FEV1(% of predicted)b | 94 (83–106) | 92 (71–114) | 59 (10–89) | P < 0.001e |
FEV1/FVC (% of predicted)b | 78 (74–82) | 78 (72–88) | 55 (41–69) | P < 0.001f |
ADAM15mRNA Levels in AMs (Normalized to Levels in AMs From Non-smokers) | 1 ± 0.3 | 1.2 ± 0.5 | 2 ± 0.4 | P < 0.001g |
ADAM15 Protein Levels in AMs (% of Levels in AMs From Non-smokers) | 100 ± 26 | 130 ± 27 | 234 ± 50 | P < 0.001h |
sADAM15 Protein Levels in BALF (pg/ml) | 7.4 (0–23) | 10 (0–25) | 7 (0–58) | NSi |
Characteristics | Non-smokersa (N = 28) | Smokersa (N = 27) | COPD GOLD stage I-II (N = 27) | COPD GOLD stage III-IV (N = 33) | P valuec |
---|---|---|---|---|---|
Number of males (%) | 18 (64.3) | 17 (63) | 23 (85) | 20 (60.6) | NS |
Age (years) | 66 (35–77) | 62 (50–74) | 67 (53–83) | 65 (48–82) | NS |
Pack-yrs. of smoking | 0 | 50 (15–96) | 60 (20–127) | 68 (12–160) | P ≤ 0.049d |
Number of current smokers (%) | 0 (0) | 3 (10) | 14 (52) | 7 (21) | P ≤ 0.03e |
FEV1(% of predicted)b | 98 (79–147) | 91 (65–119) | 65 (50–105) | 35 (17–49) | P < 0.001f |
FEV1/FVC (% of predicted)b | 77 (70–86) | 76 (71–84) | 57 (38–68) | 39 (26–59) | P < 0.001g |
Plasma sADAM15 Levels (pg/ml) | 665 (175–2457) | 642 (256–2393) | 517 (64–1110) | 672 (54–3533) | NSh |
Characteristics | Non-smokersa (N = 10) | Smokersa (N = 10) | COPD GOLD stages I-II (N = 14) | COPD GOLD stages III-IV (N = 17) | P valuec |
---|---|---|---|---|---|
Number of males (%) | 4 (40) | 4 (40) | 9 (64) | 7 (41) | NS |
Age (years) | 63 ± 12 | 65 ± 9 | 65 ± 10 | 61 ± 7 | NS |
Pack-yrs. of smoking | 0 | 38 (10–84) | 62 (18–120) | 42 (13–80) | P < 0.001d |
Number of current smokers (%) | 0 (0) | 2 (20) | 1 (7) | 0 (0) | NS |
FEV1(% of predicted)b | 97 (60–133) | 87 (70–108) | 72 (50–115) | 24 (13–46) | P ≤ 0.03e |
FEV1/FVC (% of predicted)b | 82 (74–111) | 81 (72–111) | 61 (40–70) | 39 (20–68) | P < 0.001f |